Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173007 | 0.86 | SMN1; SMN2 (0.46) | CHKAPORCNHRH3CNR1CNR2 | |
| SCHEMBL3166116 | 0.84 | CHKA (0.42) | CHKAPORCNHRH3CNR1CNR2 | |
| SCHEMBL27534007 | 0.84 | ELANE (0.50) | PIM1SYKELANEARMAT2A | |
| SCHEMBL7497512 | 0.84 | ELANE (0.50) | PIM1SYKELANEARMAT2A | |
| SCHEMBL13723947 | 0.83 | GFER (0.45) | PIM1SYKELANEARPIK3CA | |
| SCHEMBL6703929 | 0.81 | SMN1; SMN2 (0.50) | CHKAPORCN | |
| SCHEMBL7918841 | 0.81 | SMN1; SMN2 (0.50) | CHKAPORCN | |
| SCHEMBL14876324 | 0.79 | SYK (0.40) | PIM1SYKELANEARMAT2A | |
| SCHEMBL2563187 | 0.79 | TRIM24 (0.47) | PIM1SYKELANEARPIK3CA | |
| Dimethylamine SCHEMBL28103398 | 0.79 | BACE1 (0.48) | SYKELANEARMAT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | PIM1 1843/4885SYK 1210/4885ELANE 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.